Commentary: Evaluating oversight of human drugs and medical devices.
This article seeks to provide insights into appropriate FDA oversight of nanotechnology. This commentary identifies limitations in the methodology employed and concludes that the analysis would be stronger with a more in-depth institutional dimension based on administrative law and political science research.
Foote
Susan Bartlett
SB
Medical Technology Leadership Forum, USA.
D003257:Consumer Product Safety; D004335:Drug and Narcotic Control; D006801:Humans; D050997:Nanomedicine / Q000331:legislation & jurisprudence*; D011050:Policy Making; D014481:United States; D014486:United States Food and Drug Administration